BioPYM Platform (Lead Program)

About Fzata

Fzata is developing a novel oral biologics platform, BioPYM®, which utilizes engineered probiotic yeast to produce therapeutics locally in the gut, aiming to treat gastrointestinal diseases without injections. The company is advancing toward its first-in-human clinical trials targeted for summer 2026, pending FDA clearance, and is preparing for a Series A financing round. With strong academic roots and over $24 million in non-dilutive NIH funding, Fzata is led by a team of scientific founders and industry veterans, positioning itself to address significant unmet needs in conditions like C. difficile infection.

Therapeutic Areas

Other Clostridioides difficile Infection (CDI) Drugs